Medina Ú, Almendra-Pegueros R, Gordillo-Moscoso A

Idioma: Inglés [English version]
Referencias bibliográficas: 15
Paginas: s225-230
Archivo PDF: 170.72 Kb.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Hernández-Alcaraz C, Aguilar-Salinas CA, Mendoza-Herrera K, Pedroza-Tobías A, Villalpando S, Shamah-Levy T et al. Dyslipidemia prevalence, awareness, treatment and control in Mexico: results of the Ensanut 2012. Salud Publica Mex. 2020; 62 (2): 137-146.

2. Graham I, Shear C, De Graeff P, Boulton C, Catapano AL, Stough WG et al. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. Eur Heart J Cardiovasc Pharmacother. 2018; 4 (2): 119-127.

3. Mohs RC, Greig NH. Drug discovery and development: role of basic biological research. Alzheimers Dement Transl Res Clin Interv. 2017; 3 (4): 651-657.

4. Thompson GR. FH through the retrospectoscope. J Lipid Res. 2021; 62: 100036.

5. Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis. 1980; 35 (3): 259-266.

6. van der Vorst EPC. High-density lipoproteins and apolipoprotein A1. In: Hoeger U, Harris JR, editors. Vertebrate and invertebrate respiratory proteins, lipoproteins and other body fluid proteins [Internet]. Cham: Springer International Publishing; 2020 [cited Jan 13, 2021]. pp. 399-420. (Subcellular Biochemistry; vol. 94). Available in: http://link.springer.com/10.1007/978-3-030-41769-7_16

7. Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014; 114 (6): 1022-1036.

8. Gómez-Restrepo C, Reveiz Narváez Y. The registration of clinical trials. Rev Colomb Psiquiatr. 2008; 37 (3): 452-456.

9. Feingold KR. Cholesterol lowering drugs. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K et al, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 [cited Jan 13, 2021]. Available in: http://www.ncbi.nlm.nih.gov/books/NBK395573/

10. Sirtori CR, Pavanello C, Bertolini S. Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia. Ann Med. 2014; 46 (7): 464-474.

11. McGowan MP, Moriarty PM, Backes JM. The effects of mipomersen, a second-generation antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia. Clin Lipidol. 2014; 9 (5): 487-503.

12. Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr Atheroscler Rep. 2020; 22 (1): 5.

13. Tomlinson B, Chan P, Zhang Y, Lam CWK. Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. Expert Opin Pharmacother. 2020; 21 (17): 2137-2151.

14. Kosmas CE, Muñoz Estrella A, Skavdis A, Peña Genao E, Martinez I, Guzman E. Inclisiran for the treatment of cardiovascular disease: a short review on the emerging data and therapeutic potential. Ther Clin Risk Manag. 2020; 16: 1031-1037.

15. Nguyen D, Du N, Sulaica EM, Wanat MA. Bempedoic acid: a new drug for an old problem. Ann Pharmacother. 2021; 55 (2): 246-251.